HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

AuthorsFrancesca Valcamonico, Fausto Petrelli, Laura Ferrari, Vittorio Ferrari, Salvatore Grisanti, Sandro Barni, Alfredo Berruti
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 32 Issue 32 Pg. 3684-5 (Nov 10 2014) ISSN: 1527-7755 [Electronic] United States
PMID25225432 (Publication Type: Letter, Comment)
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
Topics
  • Adenocarcinoma (drug therapy, secondary)
  • Bone Density Conservation Agents (therapeutic use)
  • Bone Neoplasms (drug therapy, secondary)
  • Diphosphonates (therapeutic use)
  • Humans
  • Imidazoles (therapeutic use)
  • Male
  • Prostatic Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: